Skip to Content

Loncar Cancer Immunotherapy ETF CNCR

Medalist Rating as of | See Loncar Investment Hub

Morningstar’s Analysis CNCR

Will CNCR outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Weakness in Loncar Cancer Immunotherapy ETF's People and Process Pillar ratings limits this strategy to a Morningstar Medalist Rating of Negative.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a sizable cost advantage over competitors, priced within the second-lowest fee quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings CNCR

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 20.9
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Geron Corp

3.05 552,261
Healthcare

ImmunityBio Inc Ordinary Shares

2.27 412,029
Healthcare

Cullinan Therapeutics Inc

2.17 393,653
Healthcare

Acrivon Therapeutics Inc

2.12 384,522
Healthcare

Deciphera Pharmaceuticals Inc

2.08 377,610
Healthcare

Enliven Therapeutics Inc

2.05 371,539
Healthcare

Janux Therapeutics Inc Ordinary Shares

2.01 365,084
Healthcare

Nuvation Bio Inc Ordinary Shares - Class A

1.91 346,128
Healthcare

Day One Biopharmaceuticals Inc

1.63 295,370
Healthcare

Revolution Medicines Inc Ordinary Shares

1.59 287,656
Healthcare